Tumours and tremors: how PTEN regulation underlies both by Kim, R H & Mak, T W
Minireview
Tumours and tremors: how PTEN regulation underlies both
RH Kim
1,2,3 and TW Mak*,1,2,3
1Campbell Family Institute for Breast Cancer Research, Toronto, Ontario M5G 2C1, Canada;
2Ontario Cancer Institute, Toronto, Ontario M5G 2C1,
Canada;
3Department of Medical Biophysics, University of Toronto, Toronto, Ontario M5G 2C1, Canada
Mutations of the tumour suppressor PTEN (phosphatase and tensin homolog deleted on chromosome 10) are seen in many human
cancers. However, dysregulation of PTEN may be involved in other disease states such as Parkinson’s disease. This minireview
describes recent work examining PTEN regulation and its implications for the development of both cancer and neurodegenerative
disease.
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PTEN AND TUMORIGENESIS
Almost a decade has passed since the discovery of the lipid
phosphatase PTEN (phosphatase and tensin homolog deleted on
chromosome 10) as an important tumour suppressor. The PTEN
gene was originally identified by three independent groups using
different methodologies: a representational difference analysis of
tumours; a high-density scan of chromosome 10q in glioma cell
lines and a screening of human cDNA libraries designed to detect
protein phosphatases upregulated in response to transforming
growth factor b (TGF-b) (Maehama et al, 2001). Mutations and
deletions in the PTEN locus were subsequently found to be
associated with a broad range of human cancers. While mutations
occur throughout the length of the PTEN gene, tumorigenic
alterations are clustered in exon 5 encoding the catalytic domain,
confirming that the PTEN lipid phosphatase activity is critical for
tumour suppression (Ali et al, 1999).
Loss of heterozygosity (LOH) studies comparing early and
advanced cancers suggest that PTEN may play its most important
role in advanced cancers of particular tissues (Ali et al, 1999). For
example, the mutation frequency of PTEN is high in malignant
glial tumours, but much more modest in lower grade gliomas and
glioneuronal tumours. Furthermore, alterations of PTEN in glial
tumours are associated with shorter median survival. Prostate
tumours are associated with LOH of 10q23, with mutations of
PTEN reported most frequently in metastatic disease and in cases
with a poor prognosis. Although second mutations of PTEN
occur less frequently than LOH, loss of PTEN protein occurs
frequently in high grade and Gleason score prostate tumours.
PTEN is also considered as the most frequently mutated gene in
endometrial cancers. Indeed, mutation of PTEN likely contributes
to the initiation of endometrial tumorigenesis, as this gene is
also altered in premalignant endometrial hyperplasia (Sansal and
Sellers, 2004).
Germline mutations in tumour suppressor genes are associated
with cancer predisposition syndromes that result in the appear-
ance of hamartomas (hyperplastic and disorganised growths)
throughout the body. Germline mutations of the PTEN gene
are found in two hamartoma disorders called Cowden syndrome
(MIM 158350) and Bannayan–Riley–Ruvalcaba (MIM 153480)
syndrome. Cowden syndrome is a rare, autosomal dominant,
familial cancer syndrome characterised by hamartomas, multiple
smooth facial papules, acral keratosis and multiple oral papillo-
mas. In contrast, Bannayan–Riley–Ruvalcaba syndrome is
marked by macrocephaly, lipomatosis, hemangiomatosis and
speckled penis (Eng, 2003). As with sporadic tumours, the
germline PTEN mutations associated with these hamartoma
syndromes are clustered around the catalytic site (Ali et al, 1999).
Enhanced tumorigenesis has also been observed in Pten-
deficient mice. Numerous conventional and conditional gene-
targeting murine models of pten deficiency have been generated to
investigate the physiological functions of PTEN. Conventional
gene-targeting of pten in all mouse tissues (pten
 /  mice) results
in developmental delay and lethality at embryonic days 6.5–8.5
due to a failure in chorio-allantoic fusion (Kishimoto et al, 2003).
However, pten
þ/  mice eventually develop LOH of the remaining
pten allele, leading to the appearance of tumours in the endo-
metrium, liver, prostate, gastrointestinal tract, thyroid and thymus.
Interestingly, in addition to tumours, tissue-specific deletion of
pten can result in hyperplasia, autoimmunity, glucose dysregu-
lation or neurological deficits (Kishimoto et al, 2003).
STRUCTURE OF THE PTEN GENE
The human genomic PTEN locus consists of nine exons encoding a
5.5kb mRNA that specifies a 403 amino-acid open reading frame.
The translation product is a 53kDa protein with extensive
homology to tensin/auxilin and protein tyrosine phosphatases
(PTPs). Studies of the crystal structure of PTEN have revealed an
enlarged catalytic site (relative to other PTPs) that accommodates
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the recruitment of proteins to the membrane (Maehama et al,
2001). In addition to the C2 domain, the C-terminus of PTEN
contains a PSD95/SAP90, DLG, ZO-1 (PDZ)-binding domain
(involved in protein–protein interactions) and two proline,
glutamic acid, serine and threonine (PEST) sequences (involved
in protein degradation) (Leslie and Downes, 2004).
FUNCTIONS OF THE PTEN PROTEIN
The N-terminus of the PTEN protein is similar to that of PTPs, and
PTEN was initially thought to be a dual specificity PTP. Indeed, the
PTP activity of PTEN has been implicated in cellular processes
such as cell motility (Raftopoulou et al, 2004). However,
PTEN removes phosphate groups from phosphorylated threonine
and serine protein targets only very inefficiently, and its lipid
phosphatase activity is now considered its most important attri-
bute. PTEN is most active against negatively charged peptides, and
its primary cellular substrate is the membrane lipid phospho-
inositide-3,4,5-trisphosphate (PIP3) (Maehama et al, 2001). Phos-
phatidylinositol 3,4,5-trisphosphate is the principal second
messenger of the phosphoinositide-3 kinase (PI30K) pathway that
mediates receptor tyrosine kinase signalling through to the
survival kinase PKB/Akt (Chan et al, 1999). Increased levels of
PIP3 at the membrane cause PH domain-containing proteins such
as PKB/Akt and PDK-1 to colocalise, resulting in PDK-1-mediated
phosphorylation and activation of PKB/Akt. Activated PKB/Akt
transfers a phosphate group to target proteins involved in cell
survival, cell cycling and metabolism (Chan et al, 1999). PTEN
exerts its tumour-suppressive effect by dephosphorylating PIP3,
thereby negatively regulating PKB/Akt activation and the PI30K
survival pathway (Maehama et al, 2001).
PTEN-mediated modulation of PI30K signalling plays a key role
in regulating cellular functions associated with proliferation/cell
cycle, programmed cell death (PCD), angiogenesis and migration.
Engineered overexpression of PTEN induces profound growth
suppression primarily by promoting cell cycle arrest. For example,
PTEN overexpression leads to G1 arrest in glioma, breast,
endometrial and prostate cancer cells (Maehama et al, 2001). This
cell cycle arrest requires PTEN’s lipid phosphatase activity, can be
enhanced by low serum, and can be rescued with the introduc-
tion of constitutively active forms of PI30K, PKB/Akt or PDK-1
(Maehama et al, 2001). One mechanism by which PTEN induces
cell cycle arrest is by regulating PKB/Akt such that levels of the cell
cycle inhibitor p27
kip1 are increased. Overexpression of PTEN also
correlates with decreased total levels and nuclear localisation of
cyclin D1, a key cell cycle molecule regulated by PKB/Akt. Other
PKB/Akt-regulated cell cycle mediators affected by PTEN expres-
sion levels include the forkhead transcription factors and glycogen
synthase kinase (Maehama et al, 2001).
In addition to regulating the cell cycle, PTEN controls various
forms of PCD. Overexpression of PTEN induces the apoptosis of
many different cell types, and pten-deficient murine embryonic
fibroblasts (MEFs) are resistant to various apoptotic stimuli
(Maehama et al, 2001). PTEN’s promotion of the apoptotic
response may cooperate with PTEN’s function in cell cycle arrest,
and may be mediated by more than one mechanism. Through its
effects on PKB/Akt, PTEN can induce the activation of proapop-
totic molecules such as Fas and bim, while promoting the
inactivation of antiapoptotic molecules such as the bcl-2 family
member Bad and the X-linked inhibitor of apoptosis (XIAP)
that blocks caspase activation. As a result, pten
þ/  mice are
abnormally susceptible to Fas-mediated apoptosis, and ectopic
expression of PTEN sensitises glioblastoma cells to irradiation-
and Fas-induced apoptosis characterised by increased caspase-3
activity (Kishimoto et al, 2003). PTEN also plays an important role
in the induction of death in cells that lose contact with the
extracellular matrix, a type of PCD called anoikis. Reconstitution
of PTEN in PTEN-deficient cells restores anoikis by negatively
regulating the scaffold protein focal adhesion kinase (FAK). A
detectable decrease in FAK phosphorylation is also observed when
PTEN overexpression results in inhibition of fibronectin-induced
formation of actin stress fibres and prevention of cell spreading,
migration on extracellular matrix proteins and invasion. Con-
versely, an absence of PTEN function may allow unregulated cell
spreading and invasion that could contribute to metastasis
(Maehama et al, 2001).
In addition to promoting the survival and metastasis of tumour
cells, PTEN mutations can contribute to malignancy through
altered regulation of protein synthesis and cellular nutrient
consumption. Through studies using the fruitfly Drosophila
melanogaster, it has been shown that PTEN inhibits the target of
rapamycin (mTOR) metabolic pathway. Dysregulation of this
pathway resulted in altered protein translation and amino-acid
consumption, which in turn led to marked increases in individual
cell size and organ size. As well, recent studies have suggested
that PTEN mutations can influence the activity of the vascular
endothelial-like growth factor (VEGF) that stimulates blood
vessel formation. Mutation of PTEN can destabilise hypoxia-
inducible transcription factor 1 (HIF-1), the molecule that
drives VEGF transcription. Thus, in the absence of PTEN, a
combination of increased metabolism and enhanced angiogenesis
may promote tumour cell growth and metastasis (Sansal and
Sellers, 2004).
REGULATION OF THE PTEN PROTEIN
Some tumours, such as sporadic breast cancers, contain wild-type
PTEN genes but decreased PTEN protein immunoreactivity. This
observation implies that dysregulation of a normal PTEN gene or
protein can abrogate PTEN function and lead to neoplastic disease.
PTEN was initially cloned as a gene whose transcription was
downregulated by TGF-b. However, in addition to transcriptional
regulation, the function of the normal PTEN protein can be
modulated by protein–protein interactions, phosphorylation and
other epigenetic factors.
The C-terminus of PTEN is critical for its tumour suppressive
activity and contains putative phosphorylation sites thought to
play a role in PTEN regulation (Leslie and Downes, 2004). Residues
Ser380, Thr382 and Thr383 are substrates for phosphorylation by
casein kinase II (CK2). Casein kinase II-mediated phosphorylation
of these residues alters electrostatic shielding and decreases
the affinity of the catalytic and C2 domains of PTEN for the
membrane, decreasing PTEN activity. Casein kinase II-mediated
phosphorylation also stabilises the PTEN protein by preventing its
proteasomal degradation and proteolysis by caspases, while
keeping it in an inactive state. Inhibition of CK2-mediated
PTEN phosphorylation results in increased PTEN activity and a
corresponding reduction in PKB/Akt activation. This activation
of unphosphorylated PTEN may be due to a conformational
change that opens the PDZ-binding sites. The presence of open
PDZ-binding sites in PTEN allows interactions with PDZ-
containing proteins such as membrane-associated guanylate
kinase inverted-2 (MAGI-2), as well as the formation of active
PTEN-associated complexes that can decrease PKB/Akt activation
(Leslie and Downes, 2004). Overexpression of MAGI-2 has been
shown to restore PTEN stability in vinculin null F9 cells, which are
cells that contain decreased PTEN protein but normal levels of
PTEN mRNA (Subauste et al, 2005). Other PDZ domain-containing
proteins that interact with PTEN include MAGI-3, hDLG (discs-
large) and hMAST (microtubule-associated serine-threonine
kinase), all of which can bind to PTEN and affect its stability
through phosphorylation of the C-terminal tail (Leslie and
Downes, 2004; Valiente et al, 2005).
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that is overexpressed in a large number of tumours. Cys32 of
thioredoxin forms a disulphide bond with Cys212 in the C2
domain of PTEN, inhibiting PTEN activity (Meuillet et al, 2004).
PTEN can also be reversibly inactivated by exposure to hydrogen
peroxide, which induces the formation of an internal disulphide
bond between Cys71 and Cys124 in the catalytic core (Lee
et al, 2002). This type of PTEN inactivation is seen in cell
cultures following growth factor-induced peroxide production,
suggesting that redox inactivation of PTEN is a physiologic
response to mitogen stimulation (Kwon et al, 2004). Consistent
with this hypothesis, increases in hydrogen peroxide specifically
induced by mitochondrial dysfunction lead to the oxidation and
inactivation of PTEN and increased PI30K signalling (Connor
et al, 2005). The ability of oxidised PTEN to regain its tumour
suppressive activity depends on the capacity of thioredoxin to
reduce the inactive form, and a total loss of PTEN function can
occur if the redox status of the cell is abnormal (Lee et al, 2002;
Kwon et al, 2004).
At the mRNA level, analyses of various tumours have shown that
methylation of the PTEN promoter can result in transcriptional
silencing of the PTEN gene (Kang et al, 2002). Interestingly, the
function of the PTEN promoter and PTEN mRNA expression
appear to be regulated by more than one transcription factor.
For example, the genomic PTEN promoter sequence contains a
GC-rich 50untranslated region that can be activated by the trans-
cription factor Sp1 to drive constitutive PTEN expression (Han
et al, 2003). Another transcription factor, early growth response-1
(Egr-1), binds to the PTEN untranslated region and activates PTEN
transcription during irradiation-induced signalling. The PTEN
promoter also contains binding sites for another irradiation-
sensitive transcription factor, p53, which has been shown to
increase levels of both PTEN mRNA and protein (Leslie and
Downes, 2004). NF-kB increases PTEN expression during cellular
differentiation but decreases PTEN transcription in cells respond-
ing to apoptotic stimuli, suggesting that NF-kB-induced transcrip-
tion of PTEN may depend on the cellular context. Finally, a ligand-
activated nuclear receptor called peroxisome proliferator-activated
receptor (PPARg) is involved in anti-inflammatory responses
thought to be mediated by transcriptionally controlled upregula-
tion of PTEN (Leslie and Downes, 2004).
USE OF D. MELANOGASTER TO INVESTIGATE PTEN
SIGNALLING
The PI30K signalling pathway regulated by PTEN is largely
conserved in metazoans, and PTEN and PI30K homologues have
been identified in many species. In addition to its effect on
translation, much has been learned about the biological functions
of PTEN and the PI30K pathway from the fruit fly, D. melanogaster.
Drosophila PI30K signalling involves homologues of insulin
receptor ligand (CHICO), the insulin/IGF-1 receptor (DInr), PI30K
(Dp110), PTEN (dPTEN) and PKB/Akt (dPKB/dAkt1) (Simpson
and Parsons, 2001). Mutation of any one of the genes encoding
these proteins produces an activation of PI30K signalling that
drives cellular expansion and proliferation and leads to increases
in cell size, cell number and organ size. Conversely, overexpression
of dPTEN or dominant-negative dPI30Ki nDrosophila embryos
triggers apoptosis similar to that observed in dPKB/dAkt1- or
dPDK1-deficient flies. In the Drosophila eye, PTEN overexpression
inhibits cell cycle progression and promotes cell death (Maehama
et al, 2001). In our own work, we used a system based on this latter
observation to isolate dPTEN regulators in a gain-of-function
screening protocol employing a P-element library. We identified
DJ-1, a putative oncogene involved in autosomal recessive early-
onset Parkinson’s disease (PD) (Bonifati et al, 2003), as a novel
suppressor of PTEN function (Kim et al, 2005a).
LINKS BETWEEN DJ-1 AND TUMORIGENESIS
Several lines of evidence suggest that DJ-1 plays a role in human
tumorigenesis. Breast cancer patients have elevated levels of serum
DJ-1 and circulating anti-DJ-1 autoantibodies compared to healthy
and non-breast cancer patients (Le Naour et al, 2001). Further-
more, DJ-1 protein is increased in primary non-small-cell lung
carcinoma samples (MacKeigan et al, 2003). As with prostate
cancer, the rate of LOH at 10q23 in the lung and breast cancers is
greater than the rate of mutation of the remaining PTEN allele.
This observation suggests that, in these cases, epigenetic regulation
of PTEN has caused its loss of function. Although the underlying
mechanism has yet to be clearly defined, it is quite possible that
faulty control of a PTEN regulator such as DJ-1 is responsible. In
lung cancer patients, an elevation in DJ-1 transcripts correlates
with a poor prognosis, particularly for Stage I disease (Kim et al,
2005a). Higher levels of DJ-1 mRNA are also present in patients
lacking mutations in Ras, a well-known molecular marker of
tumorigenesis. These data suggest that DJ-1 is important for
tumour initiation and may be a useful prognostic marker in certain
types of lung cancer. In primary breast cancer samples, DJ-1
expression correlates positively with phospho-PKB/Akt immunor-
eactivity. In vitro, DJ-1 inhibits PTEN’s negative regulation of the
PI30K pathway and increases PKB/Akt activation. Thus, DJ-1 is
likely oncogenic because of its negative regulatory effects on
PTEN, effects that indirectly promote activation of the PI30K cell
survival pathway.
LINKS BETWEEN PTEN, DJ-1 AND PD
Parkinson’s disease and cancer are two pathologic processes
resulting from excessive signalling by one of two sets of opposing
forces: those driving cell death and those promoting cell survival.
Parkinson’s disease results from the excessive death of dopami-
nergic neurons in the substantia nigra pars compacta (SNpc) in the
brain, while tumorigenesis is driven by excessive cell survival
in the target tissue. The underlying signalling mechanisms of cell
death and survival can be generalised and applied to most cell
types and tissues, implying that the balance can be shifted from
death to survival and vice versa by aberrations of the same
signalling pathway. Early epidemiological studies showed a
decreased incidence of cancer in PD patients, later confirmed in
larger studies (West et al, 2005). Moreover, the genes associated
with familial forms of PD (the PARK loci) are now implicated in
tumorigenesis. For example, a-synuclein (SNCA; PARK1) expres-
sion is upregulated in glioma cell lines, schwannomas, medullo-
blastomas and breast and ovarian carcinomas. Deletions of Parkin
(PARK2) have been identified in hepatocellular carcinomas and in
breast, ovarian and non-small-cell lung cancers. Finally, ubiquitin
C-terminal hydrolase (UCH-L1; PARK5) is overexpressed in
oesophageal and squamous cell carcinomas, and in pancreatic
and colorectal cancers (West et al, 2005). The effects of PARK
mutations on tumorigenesis are unclear and, due to the unknown
functions of these PD-associated genes, conclusions about the
nature of these mutations (gain-of-function vs loss-of-function)
are difficult to establish. Moreover, loss/gain-of-function muta-
tions in PD may have additional distinct effects on tumorigenesis,
confounding attempts to ‘pigeon-hole’, a particular gene. Never-
theless, genes associated with familial PD have been shown to
regulate cell death and/or the cell cycle, and several lines of
evidence imply that malfunction of a shared biochemical pathway
may lead to PD or cancer. Firstly, during tumorigenesis, the
degradation of p27
kip1 can be driven by either PTEN or UCH-L1
(Caballero et al, 2002; Viglietto et al, 2002). Secondly, deletions of
the Parkin gene in Drosophila result in PKB/Akt activation
(Yang et al, 2005). Thirdly, PINK1, which encodes a kinase
downregulated in the absence of PTEN, has been identified as the
sixth locus (PARK6) associated with familial PD (West et al, 2005).
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isolated originally as PARK7. The identification of loss-of-function
mutations in the DJ-1 gene in PARK7 PD families is consistent with
the notion that DJ-1 acts to promote neuron survival via the PI30K
signalling pathway. The biochemistry of the neurodegeneration in
PD points to mitochondrial oxidative stress as the mechanism
driving neuronal death in the SNpc. In Drosophila, an siRNA-
induced reduction of DJ-1 causes neurons to become hyper-
sensitive to oxidative stress, and these flies show neurodegenera-
tion that is exacerbated by coexpression of PTEN (Yang et al,
2005). Significantly, this hypersensitivity to oxidative stress is also
seen in the neurons of dj-1-deficient mice (Kim et al, 2005b). In
both organisms, the increased susceptibility to oxidative stress can
be rescued by activation of the PI30K pathway (Kim et al, 2005b;
Meulener et al, 2005; Yang et al, 2005). Other work has implicated
DJ-1 as a sensor of reactive oxygen species and as a molecular
chaperone (Shendelman et al, 2004), and DJ-1 may be able to
influence the protein stability or oxidative state of elements of the
PI30K pathway. For example, PTEN and ASK1, a component of a
DJ-1-containing complex (Junn et al, 2005), are both regulated by
thioredoxin (Meuillet et al, 2004). These findings suggest that DJ-1
may act in cooperation with redox-sensitive proteins to regulate its
substrates, and that DJ-1-mediated regulation of one of these
substrates, PTEN, plays a vital role in preventing both cancer and
neurodegenerative disease.
CONCLUSIONS AND PERSPECTIVES
The tumour suppressor gene PTEN is currently recognised as one
of the most frequently mutated genes in human cancers. As befits a
critical gene, PTEN is regulated at multiple levels, including
transcription, protein stability and phosphorylation. Understand-
ing this regulation is crucial for the effective design of novel cancer
therapeutics. Inhibitors of the PI30K pathway such as wortmannin
and LY294002 are commonly employed in the research laboratory,
while receptor tyrosine kinase inhibitors such as gefitinib (Iressa;
AstraZeneca, Wilmington, DE, USA), trastuzumab (Herceptin;
Genentech, San Francisco, CA, USA) and imatinib (Gleevec;
Novartis, Summit, NJ, USA) have been added to the clinical
armamentarium used to treat certain types of human cancers.
Inhibitors of downstream effectors of the PI30K pathway, such as
the rapamycin derivatives CCI-779 (Wyeth Research, Madison, NJ,
USA) and RAD001 (Novartis) are under investigation to determine
their efficacy as mTOR inhibitors in tumours. Similarly, because
oxidative stress and reactive oxygen species can inactivate PTEN,
alternative therapeutics that target PTEN’s redox status are in the
development phase.
The involvement of the PI30K pathway and putative regulators of
PTEN (such as DJ-1) in PD indicates that the importance of PTEN
regulation extends beyond the known roles of this gene in
tumorigenesis, hamartomatous syndromes and autoimmunity. As
PTEN is regulated by phosphorylation and degradation via the
ubiquitin–proteasome system, proteasomal targeting may offer a
potential therapeutic modality for the treatment of PTEN-related
cancers. For example, the proteasome inhibitor bortezomib
(Velcade; Millennium Pharmaceuticals, Cambridge, MA, USA)
has been effective in treating multiple myeloma because survival
factors that depend on proteasomal degradation (such as NF-e ˆB)
are inactivated. However, caution is warranted in using this
approach, as other proteasome inhibitors induce Parkinsonian-like
symptoms when administered to rats (McNaught et al, 2004).
Intriguingly, this latter finding offers additional support for the
hypothesis that cancer and PD may both result from PTEN
dysregulation. All these developments point towards exciting new
avenues for the complete elucidation of PTEN’s physiological
functions, and the manipulation of this knowledge for the
treatment of both tumorigenesis and neurodegeneration.
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